Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

PLRX Pliant Therapeutics, Inc. Common Stock
$0.69 -0.57% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy PLRX stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Pliant Therapeutics, Inc. Common Stock (PLRX)

Loading

Key Stats

Market cap. 43.0M
Enterprise value -83535800
Trailing PE -0.28534980467808
Forward PE -0.5356494
PEG Ratio 0.0057885246091839
Enterprise to EBITDA 0.93
Price to book MRQ 0.23506273

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
EBITDA -89866000
Diluted EPS TTM -1.46
Total Cash (MRQ) 158.1M
Current ratio (MRQ) 9.897
Operating Cash Flow (TTM) -70895000

PLRX trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent PLRX News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.